ARTICLE | Company News
Bio-Reference Laboratories, Myriad Genetics diagnostic news
March 2, 2015 8:00 AM UTC
Myriad and Bio-Reference’s GeneDx Inc. subsidiary reached a settlement to dismiss patent litigation related to the breast cancer 1 early onset (BRCA1) and BRCA2 genes. Myriad promised not to sue GeneDx under the patents asserted in the litigation, and GeneDx will continue to provide breast cancer diagnostics. In October 2013, Myriad filed the complaint against GeneDx in the U.S. District Court for the District of Utah. GeneDx offers breast cancer diagnostic services, including testing for mutations in the BRCA1 and BRCA2 genes. ...